Pain Management Drugs Market - Global Forecast to 2026

Pain Management Drugs Market - Global Forecast to 2026

Pain management drugs are prescribed in serious to mild pain conditions such as back pain, neck pain, and pain from cancer. Pain management drugs market is highly lucrative due to low availability of alternative drug therapies for treatment of pain. Drug manufacturers are introducing effective generic version in various dosage forms, which is driving the market growth. Chronic pain is one of the highly prevalent pain disorders, which is primarily treated by these medications. The medical management of pain diseases is patient specific and is highly dependent on individual patients’ symptoms.
Market Dynamics
The global pain management drugs market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. Increasing number of major drugs such as OxyContin, Opana ER, and Celebrex have lost patent protection due to which generic manufacturers have developed generic version with product variations fostering growth of the pain management drugs market. Continuous requirement of the medication coupled with easy availability is expected to boost the adoption of pain drugs over the forecast period. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as cancer (leading to cancer pain) are fueling growth of the pain management drugs market. However, life threatening side effects associated with these medications, as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the pain management drugs market.
Key features of the study:

• This report provides in-depth analysis of pain management drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018–2026), considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global pain management drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global pain management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pain management drugs market

Detailed Segmentation:

• Global Pain Management Drugs Market, by Drug Class:
• Opioids
• NSAIDs
• Anticonvulsants
• Antidepressants
• Others
• Global Pain Management Drugs Market, by Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Pain Management Drugs Market, by Region:
• North America
• By Drug Class:
• Opioids
• NSAIDs
• Anticonvulsants
• Antidepressants
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• U.S.
• Canada
• Europe
• By Drug Class:
• Opioids
• NSAIDs
• Anticonvulsants
• Antidepressants
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Drug Class:
• Opioids
• NSAIDs
• Anticonvulsants
• Antidepressants
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• By Drug Class:
• Opioids
• NSAIDs
• Anticonvulsants
• Antidepressants
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• Brazil
• Mexico
• Rest of Latin America
• Middle East
• By Drug Class:
• Opioids
• NSAIDs
• Anticonvulsants
• Antidepressants
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Drug Class:
• Opioids
• NSAIDs
• Anticonvulsants
• Antidepressants
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• Central Africa
• South Africa
• North Africa
• Company Profiles
• Pfizer, Inc.*
• Company Overview
• Product Portfolio
• Financial Performance
• Key Strategies
• Recent Developments
• Sanofi S.A.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Abbott Laboratories
• Purdue Pharma L.P.
• GlaxoSmithKline Plc
• Johnson & Johnson
• F. Hoffmann La Roche Ltd.

“*” marked represents similar segmentation in other categories in the respective section.